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Metalloproteolytic balance in asthma: When and
how could its regulation?Matrix metalloproteinases (MMPs) are a family of secreted
and cell surface-bound neutral proteinases, active on
a large array of extracellular and cell surface proteins
under normal and pathological conditions.1 First described
as proteases that can degrade extracellular matrix (ECM)
components, MMPs may also act on a variety of extracel-
lular substrates to activate latent forms of mediators, such
as antimicrobial peptides, cytokines and growth factors, or
alter protein functions, such as shedding of cell-surface
molecules.1e3 In the lung, as in other organs, MMPs are
produced by airway epithelial and mesenchymal cells, but
also by a variety of inflammatory cells and their synthesis is
tightly regulated, via multiple activators and repressors
pathways, by hormones, cytokines, cell adhesion molecules
and a variety of environmental factors.4e6 Expressed and
secreted in inactive form, MMPs undergo multistep activa-
tion and inactivation processes in the extracellular milieu,
the most important endogenous inhibitors being the ‘‘tissue
inhibitors of matrix metalloproteinases’’ (TIMPs).6
In health and disease, a correct balance between MMPs
and TIMPs may prevent an exaggerated ECM deposition or an
alteration in its composition, but may also regulate the
activation and the cleavage of a variety of molecules
involved in wound healing, inflammation and immunity and
host defense against pathogens.4e7 Imbalance in MMPs/
TIMPs ratio has been detected in the acute and/or the
chronic phases of a variety of respiratory disorders, including
chronic obstructive pulmonary disease and asthma.8e10
In asthma, inappropriate expression and secretion of
MMP-2, MMP-3 and MMP-9 and the ADAM family were repor-
ted and thought to be part of the physiology of this dis-
order.8e11 Most of the studies performed have been focused
on the presence and/or the activity of MMP-9 (also called
gelatinase B), a protease found to be highly expressed in the
airways of asthmatic patients, compared with normal indi-
viduals,12 and specifically in patients with severe disease or
during spontaneous asthma exacerbations.13 In agreementDOI of original article: 10.1016/j.rmed.2009.03.018.
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doi:10.1016/j.rmed.2009.06.010with the concept that mediators released by activated
parenchymal and inflammatory cells could induce MMPs
secretion and activation, increase in MMP-9 activity and
elevated MMP-9/TIMP-1 ratios were reported after allergen
challenge in mild asthma.14,15 In addition, a significant
correlation was detected between airway MMP-9 levels after
allergen provocation, and the fall in FEV1 during the late-
phase bronchoconstrictive response.16 On the contrary,
under baseline conditions, a reduction in the induced
sputum MMP-9/TIMP-1 ratio was observed, with almost no
active MMP-9 because of the very large TIMP-1 excess.15
Finally, significant inverse correlations were demonstrated
between MMP-9/TIMP-1 molar ratios and the degree of
airway obstruction17 or the magnitude of high-resolution
computed tomography scan lung abnormalities.18 All these
observations suggest that in asthma the degree of MMP
activity can be linked to intensity of the inflammatory
processes in the airways and that the MMPs/TIMPs balance
could have a role in the pathogenesis of airflow limitation
and reflect the extent of structural changes in the lung.9,13,19
Little information is available on the role of the other
MMPs and their balance with TIMPs. Increased gelatinolytic
activity linked to MMP-2 (and to MMP-9), associated with
higher TIMP-1 levels were detected in patients with
asthma,20 while elevated concentrations of MMP-3 (and of
MMP-9) in active form were reported in the airways of
subjects ventilated because of acute severe asthma exac-
erbations.21 Therefore, it is likely that MMPs production and
activation and the balance with their inhibitors could
represent a dynamic protective mechanism, finalized: a) to
prevent tissue destruction, down-regulating the excessive
MMPs proteolytic activity in stable conditions; b) to favor
ECM degradation during wound healing, when necessary;
c) to modulate the inflammatory responses, in the acute
phases of an inflammatory event.9,13
What is not known is whether molecules currently used
in asthma treatments have any effect on the expression,
activation and function of MMPs and/or of their major
inhibitors, TIMP-1. Despite the demonstration that in
asthma inhaled steroids are able to reduce various.
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eceptor agonists, may modulate airway epithelial cell and
fibroblast activities,23,24 their capability to interfere with
the various MMPs activities has not yet been evaluated.13,25
In this edition of Respiratory Medicine, Todorova L
et al.26 report their results of an in vitro model on the
modulation of MMPs secretion and activation by an inhaled
steroid, budesonide, and a long-acting b2-adrenoreceptor
agonist (LABA), formoterol. They stimulated human lung
fibroblasts with TGFb1, one of the most potent growth
factors involved in the pathogenesis of tissue remodeling
and observed: a) a significant increase in the production of
proteoglycan, a major ECM components; b) an enhance-
ment, at different levels, in the production of TIMP-1 and of
three major matrix metalloproteinases, MMP-2, MMP-3 and
MMP-9. The end result was a general ‘‘pro-proteolytic’’
environment, due to the increase of the MMP-9 or MMP-2 to
TIMP-1 ratio, but not of the MMP-3/TIMP-1 ratio. Incubation
with budesonide and formoterol significantly decreased
proteoglycan production and dramatically reduced the
increase in MMP-9/TIMP-1 ratio, while the MMP-2/TIMP-1
ratio was even further enhanced because the two drugs had
no effects on MMP-2 but completely counteracted the
TGFb1-induced TIMP-1 increase. The author’s conclusion
was that budesonide/formoterol combination therapy may
counteract excessive ECM production and deposition and
thus airway fibrotic remodeling in asthma.
No question that a variety of issues stand out. Firstly, the
complex regulation of the balance between the different
MMPs and their inhibitors, observed in a simplified in vitro
model and performed on one cell line using a single inducer,
TGFb might not reflect in vivo mechanisms. Secondly, the
surprising activity of budesonide/formoterol combination
on the TGFb-induced fibroblast activation, leading to
opposite effects on MMP-9/TIMP-1 and MMP-2/TIMP-1 ratios
has not been confirmed in human asthma. Thirdly, the
limited knowledge that we have in ‘‘real life’’ on:
a) the interaction between the mediators released in the
asthmatic airways and MMPs and TIMPs production and
activation; b) the specific activity of MMPs on their various
targets, including cytokines, chemokines and growth
factors; c) the modulation by current pharmacologic
treatment of MMP/TIMP production, activation and inhibi-
tion; d) the role of MMPs and TIMPs in the various asthma
phenotypes and in patients of different age. This may be
even more relevant in early childhood, a period of life when
a significant progressive decrease in lung function may
occur.27 There is experimental evidence that MMP-9 may
play an important role in oxygen-induced lung injury in
bronchopulmonary dysplasia,28 while disregulation of MMP-
9/TIMP-1 homeostasis in the airways may be present in
infants with respiratory syncytial or parainfluenza virus
induced bronchiolitis.29 In addition, extremely high levels
of MMP-9 and its inhibitor TIMP-1 (about 30-fold and 35-
fold) were observed in bronchoalveolar lavage cells in
children with severe asthma.30 It is therefore possible that
the presence of protease/antiprotease disequilibrium may
have a more significant pathogenetic role early in life, in
the extremely plastic, still growing lung.
Taken together, these data identify MMPs as potential
therapeutic targets. However, because of the intricacy ofthese enzymes and their substrates, the complexity of the
interaction between inflammation and remodeling and the
dynamic balance with their inhibitors, it is not clear
whether MMP downregulation would be beneficial or
harmful and in which situations it would be of clinical help.
There is no doubt that we need more information to fill the
many holes that we have to provide effective treatments to
our patients and to identify efficient secondary and tertiary
prevention measures. The good news is that, as shown by
Todorova L et al. in vitro,26 an inhaled corticosteroid/LABA
combination, besides being highly effective in symptoms
control,31 might also have the potential to counteract
a protease/antiprotease disequilibrium induced by pro-
inflammatory or pro-fibrotic mediators.
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